With over 2 million cancer cases and over 600,000 cancer-associated
deaths predicted in the U.S. for 2022, this life-debilitating disease
continuously impacts the lives of people across the nation every day.
Therapeutic treatment options for cancer have historically involved
chemotherapies to eradicate tumors with cytotoxic mechanisms which
can negatively affect the efficacy versus toxicity ratio of treatment.
With a need for more directed and therapeutically active options,
targeted small-molecule inhibitors and immunotherapies have since
emerged to mitigate treatment-associated toxicities. However, aggressive
tumors can employ a wide range of defense mechanisms to evade monotherapy
treatment altogether, resulting in the recurrence of therapeutically
resistant tumors. Therefore, many clinical routines have included
combination therapy in which anticancer agents are combined to provide
a synergistic attack on tumors. Even with this approach, maximizing
the efficacy of cancer treatment is contingent upon the dose of drug
that reaches the site of the tumor, so often therapy is administered
at the site of a tumor via localized delivery platforms. Commonly
used platforms for localized drug delivery include polymeric wafers,
nanofibrous scaffolds, and hydrogels where drug combinations can be
loaded and delivered synchronously. Attaining synergistic activity
from these localized systems is dependent on proper material selection
and fabrication methods. Herein, we describe these important considerations
for enhancing the efficacy of cancer combination therapy through biodegradable,
localized delivery systems.